SCHEMBL5074293

SCHEMBL5074293

CCCCN(Cc1cccc(OC)c1)Cc1c(-c2ccccc2)nc(-c2ccccc2)n1CCC

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CALM1 P0DP23 1/20 0.45
CAMKK2 Q96RR4 1/20 0.45
TLR7 Q9NYK1 1/20 0.41
C5AR1 P21730 1/20 0.41
BCHE P06276 3/20 0.40
NR1H2 P55055 1/20 0.39
NR1H3 Q13133 1/20 0.39
ALDH1A1 P00352 2/20 0.39
KDM4E B2RXH2 1/20 0.39
LMNA P02545 1/20 0.39
GAA P10253 1/20 0.39
TSHR P16473 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
F2R P25116 3/20 0.39
MEN1 O00255 2/20 0.39
KMT2A Q03164 2/20 0.39
ATP4A P20648 2/20 0.39
ATP4B P51164 2/20 0.39
CRHR1 P34998 2/20 0.39
CNR2 P34972 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5135705 0.96 CALM1 (0.45) CALM1CAMKK2TLR7C5AR1BCHE
SCHEMBL5134931 0.95 CALM1 (0.44) CALM1CAMKK2TLR7C5AR1BCHE
SCHEMBL5170566 0.94 CALM1 (0.43) CALM1CAMKK2TLR7C5AR1BCHE
SCHEMBL5137491 0.93 CALM1 (0.45) CALM1CAMKK2TLR7C5AR1BCHE
SCHEMBL5072289 0.91 ABCB1 (0.42) CALM1CAMKK2TLR7C5AR1BCHE
SCHEMBL5137571 0.91 POLB (0.42) CALM1CAMKK2TLR7C5AR1NR1H2
SCHEMBL5135433 0.90 C5AR1 (0.46) CALM1CAMKK2TLR7C5AR1BCHE
SCHEMBL5135383 0.90 C5AR1 (0.45) CALM1CAMKK2TLR7C5AR1BCHE
SCHEMBL5136852 0.89 ALDH1A1 (0.46) C5AR1BCHEALDH1A1KDM4ELMNA
SCHEMBL5138089 0.89 TSHR (0.46) C5AR1BCHEALDH1A1KDM4ETSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1490044-A4 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORP (US) 2008-04-16 EP disclosed
EP-1490044-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2004-12-29 EP disclosed
WO-2003084524-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2003-10-16 WO disclosed